Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
203.98
+2.76 (1.37%)
At close: Apr 28, 2026, 4:00 PM EDT
188.98
-15.00 (-7.35%)
After-hours: Apr 28, 2026, 7:59 PM EDT
Jazz Pharmaceuticals Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Jazz Pharmaceuticals stock have an average target of 217.57, with a low estimate of 172 and a high estimate of 275. The average target predicts an increase of 6.66% from the current stock price of 203.98.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Jazz Pharmaceuticals stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 4 | 4 |
| Buy | 8 | 8 | 8 | 9 | 8 | 9 |
| Hold | 2 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 16 | 13 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $215 → $225 | Buy | Maintains | $215 → $225 | +10.30% | Apr 22, 2026 |
| Barclays | Barclays | Buy Maintains $224 → $225 | Buy | Maintains | $224 → $225 | +10.30% | Apr 20, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $219 → $232 | Buy | Maintains | $219 → $232 | +13.74% | Mar 19, 2026 |
| Barclays | Barclays | Buy Initiates $224 | Buy | Initiates | $224 | +9.81% | Feb 27, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $191 → $195 | Buy | Maintains | $191 → $195 | -4.40% | Feb 25, 2026 |
Financial Forecast
Revenue This Year
4.53B
from 4.27B
Increased by 6.22%
Revenue Next Year
4.88B
from 4.53B
Increased by 7.68%
EPS This Year
24.24
from -5.84
EPS Next Year
25.45
from 24.24
Increased by 4.99%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 4.7B | 5.4B | ||||||
| Avg | 4.5B | 4.9B | ||||||
| Low | 4.3B | 4.4B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 11.1% | 18.2% | ||||||
| Avg | 6.2% | 7.7% | ||||||
| Low | 0.0% | -2.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 27.54 | 31.56 | ||||||
| Avg | 24.24 | 25.45 | ||||||
| Low | 21.45 | 21.30 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 30.2% | ||||||
| Avg | - | 5.0% | ||||||
| Low | - | -12.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.